Cargando…
Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary outcomes of randomized controlled trial
Apart from all the gloominess, the COVID-19 Pandemic has a silver lining of bringing a renaissance as Ayurveda and integrated medicine are becoming a choice for acute as well as infective diseases. Here we report outcomes of a preliminary work, the randomized controlled trial (CTRI/2021/02/031256) o...
Autores principales: | Jamadagni, Sameer, Pandkar, Prasad, Saundankar, Tushar, Shirke, Girish, Malekar, Shailesh, Vaidya, V.G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127050/ https://www.ncbi.nlm.nih.gov/pubmed/35634544 http://dx.doi.org/10.1016/j.jaim.2022.100590 |
Ejemplares similares
-
Rasayans and non-rasayans herbs: Future immunodrug – Targets
por: Doshi, Gaurav Mahesh, et al.
Publicado: (2013) -
Vidyarthimitra Vaidya Madhav Vasudev Kolhatkar
por: Gadgil, Vaidya Dilip
Publicado: (2012) -
Dr. Anant Madhav Deshpande
por: Momin, Shakil
Publicado: (2012) -
Ayurvedic lipid based rasayans - A perspective on the preparation and pharmacological significance of lipids on the bioavailability of phytoconstituents
por: Bali, Sharadendu, et al.
Publicado: (2022) -
Pathophysiology of Covid-19 and host centric approaches in Ayurveda
por: Pandkar, Prasad Dilip, et al.
Publicado: (2022)